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Abstract 
Paroxysmal non-kinesigenic dyskinesia (PNKD) is a rare autosomal dominant movement disorder triggered by stress, fatigue or 
consumption of either alcohol or caffeine. Attacks last 1–4 h and consist of dramatic dystonia and choreoathetosis in the limbs, 
trunk and face. The disease is associated with single amino acid changes (A7V or A9V) in PNKD, a protein of unknown function. 
Here we studied the stability, cellular localization and enzymatic activity of the PNKD protein in cultured cells and transgenic 
animals. The N-terminus of the wild-type (WT) long PNKD isoform (PNKD-L) undergoes a cleavage event in vitro, resistance to 
which is conferred by disease-associated mutations. Mutant PNKD-L protein is degraded faster than the WT protein. These results 
suggest that the disease mutations underlying PNKD may disrupt protein processing in vivo, a hypothesis supported by our 
observation of decreased cortical Pnkd-L levels in mutant transgenic mice. Pnkd is homologous to a superfamily of enzymes with 
conserved β-lactamase domains. It shares highest homology with glyoxalase II but does not catalyze the same reaction. Lower 
glutathione levels were found in cortex lysates from Pnkd knockout mice versus WT littermates. Taken together, our results 
suggest an important role for the Pnkd protein in maintaining cellular redox status.
INTRODUCTION 
Dystonia is the third most common movement disorder, affecting ~30 of every 100 000 individuals worldwide. It is characterized by 
abnormal posture and involuntary muscle contraction (focal or generalized) (1–3). Paroxysmal non-kinesigenic dyskinesia (PNKD, 
DYT8) is an early-onset autosomal dominant movement disorder characterized by episodic attacks of any combination of dystonia, 
chorea and athetosis. Attacks can be precipitated by consumption of alcohol or coffee, hunger, fatigue, stress and menstruation 
(1,4,5). PNKD is a monogenic disease with nearly complete penetrance. We previously reported the discovery of Ala→Val 
substitutions in the PNKD protein at either seventh or ninth positions that cause the disease (4), and a third mutation (A33P) was 
recently reported in a separate study (6). The protein sequence of PNKD contains a β-lactamase domain, suggesting it belongs to 
an enzyme superfamily found from prokaryotes to primates. Human glyoxylase II, also named hydroxyacylglutathione hydrolase 
(HAGH), is the closest homolog of PNKD in Homo sapiens and catalyzes the second enzymatic step in the glutathione-dependent 
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glyoxylase pathway which converts methylglyoxal (MG), a toxic by-product of glycolysis, to D-lactic acid (7). The shared β-
lactamase domain of PNKD shows 44% identity and 58% similarity to HAGH.
The human PNKD gene contains 12 exons and encodes at least three different isoforms (4). The long (PNKD-L) and medium 
(PNKD-M) isoforms contain the β-lactamase domain in the C-terminus, and the short form (PNKD-S) contains three exons with no 
homology to any known protein. PNKD point mutations exist in the first exon and are shared by the long and short forms. Of the 
three isoforms, the long form is expressed only in the central nervous system (CNS), while the medium and short forms are widely 
expressed. Although the β-lactamase domains of PNKD-L and HAGH share a high degree of similarity, the normal function of 
Pnkd-L and the molecular dysfunction of mutant PNKD-L remain unknown.
MG is an endogenous byproduct generated by several metabolic pathways, including glycolysis, lipid peroxidation and threonine 
catabolism, with glycolysis being the major source (7,8). MG, an active glycation reagent, is toxic and mutagenic due to the 
reactivity of its aldehyde group with guanine residues of DNA and amino acid nucleophiles. MG is generally found at very low 
levels in cells and is detoxified mainly through the glyoxalase pathway. MG reacts with reduced glutathione, forming a 
hemithioacetal that is converted to S-D-lactoyl-glutathione (SLG) by glyoxalase I. Glyoxalase II (HAGH in human) then hydrolyzes 
SLG to D-lactate and reduced glutathione (4,7). Glutathione is a prominent scavenger of reactive oxygen species in cells (9). 
Furthermore, in neurodegenerative diseases and animal models of brain injury, glutathione is a measure of neuronal redox status 
(10,11).
In this study, we focused on the long isoform of PNKD and characterized wild-type (WT) and mutant PNKD-L enzymatic activity, 
protein stability and cellular localization. We found the disease mutations decreased PNKD-L protein stability and prevent an N-
terminus cleavage event. Pnkd-deficient mice have lower brain glutathione levels and impaired motor coordination. Our findings 
suggest that Pnkd-L is involved in regulating cellular redox status through a reaction regenerating reduced glutathione, and 
disease mutations cause more rapid degradation and decreased endogenous Pnkd-L levels in the cortex. We previously reported 
that PNKD-L localizes to cellular membrane in HEK293 cells, but a recent study suggested mitochondrial localization of PNKD-L in 
Cos7 cells (6). Here we sought to clarify whether these contradictory localization patterns were due to differences in the two cell 
lines used and to study localization in a more relevant (‘neuron-like’) cell line (SH-SY5Y) using our anti-PNKD antibodies.
RESULTS 
Disease mutations affect PNKD stability 
When expressing PNKD-L from cultured cells, we observed lower protein levels for the mutant versus WT protein. This result was 
confirmed for both long and short isoforms (Fig. A), suggesting that disease-causing mutations may affect protein degradation 
rates. We used cycloheximide (CHX) to halt protein synthesis and measured protein degradation rates of WT and MUT PNKD-L. 
The CHX-chase assay revealed shortened half-life of MUT PNKD-L in cultured cells (Fig. B). A 35S labeled pulse chase assay 
further confirmed this difference in degradation rates (Fig. C). MUT PNKD-L is degraded faster than WT PNKD-L, resulting in 
lower protein levels. To further examine degradation in vivo, we crossed mut-Tg mice onto the knock-out (KO) background so that 
only mutant Pnkd-L was expressed in the brain, and compared the mutant protein with the WT protein in littermate controls (Fig. 
D). Pnkd-L protein levels decrease significantly when only the mutant Pnkd-L protein is expressed (lane 4), when compared with 
one copy of WT Pnkd-L in its littermates (lane 1). Transcript levels of Mut-Tg Pnkd are not significantly different from endogenous 
Pnkd (Supplementary Material, Fig. S1).  
Proteins are degraded in different pathways, including proteasomes, lysosomes or by autophagy. We used specific inhibitors to 
determine which pathway(s) are responsible for degradation of WT and MUT PNKD-L. Proteasomal and lysosomal degradation 
pathways were blocked either independently or together and PNKD-L protein degradation was analyzed. In cultured HEK293 cells, 
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overexpressed PNKD-L is found in both membrane and cytosolic fractions (Fig. A). PNKD-L accumulated in the membrane 
fraction with the inhibition of proteasome (lactacystine), lysosome (chloroquine) or both pathways (MG-132) (Fig. B, lanes 2–4). In 
addition, 3-MA, an inhibitor of autophagy, led to the accumulation of MUT (but not WT) PNKD-L compared with dimethyl sulfoxide 
(DMSO) control (Fig. B, lane 5), although to a lesser extent compared with proteasome inhibitors (Supplementary Material, Fig. 
S2). Integrin αV was used as a transmembrane protein control and is mainly degraded through the lysosomal pathway (Fig. B, 
lanes 3 and 4). Cytosolic PNKD-L WT and MUT proteins are primarily degraded through the ubiquitin–proteasome-dependent 
pathway (Fig. C, lane 2). This suggests that shortened half-life of the MUT protein results from autophagy of membrane-
associated PNKD-L.  
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Cleavage of the WT PNKD N-terminus 
When a FLAG tag is attached to the N-terminus of the PNKD-L WT, or PNKD-L MUT, or a homologous protein, HAGH, it can be 
detected on all but the PNKD-L WT form, even though both WT and MUT PNKD-L are expressed and detected by the anti-PNKD-
L antibody (Fig. A). C-terminal Myc or FLAG tags can be detected in all fusion proteins (data not shown). We speculated that the 
N-terminal tag may be cleaved from WT proteins. To test this, we engineered clones to express the different isoforms as fusions 
with a larger tag (GFP) on the N-terminus (WT and MUT (both L and S forms), and a truncated N-terminus [amino acids 1–79 of 
PNKD (N79)]. Using an anti-GFP antibody, a cleaved band was detected in WT (both L and S forms) and N79 (its size slightly 
larger than GFP alone) indicating that some of the N-terminus was cleaved in both PNKD-L and S forms (Fig. B, Supplementary 
Material, Fig. S3A). The MUT forms do not show a cleavage product (Fig. B, lanes 4 and 6). Based on the size difference 
between cleaved GFP and GFP alone, the cleaved N-terminus was estimated to be ~15–30 amino acids in length. We speculate 
that the cleavage resistance is caused by point mutations in N-terminus of PNKD-L, such as A7V, A9V (4) or A33P (6). To further 
test this hypothesis, we generated these disease-causing mutations (A7/9V, A33P) and additional point mutations at residues 
close to the human mutations (A15G, R16G). In addition, one-point mutation downstream of the cleavage site was generated 
(C85G). The A7/9V, A33P, A15G and R16G mutations are all cleavage resistant, while the C85G mutation has no effect on 
cleavage (Fig. C). In a CHX-chase assay, the A33P and A15G mutants also show faster degradation versus WT forms (Fig. D 
and Supplementary Material, Fig. S3B and C). These results demonstrate that point mutations within the N-terminus of PNKD can 
prevent protein cleavage and are associated with decreased protein stability.  
3
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N-terminal mutations of PNKD-L do not affect WT protein stability 
We next examined the ability of PNKD-L to multimerize. Fragments of PNKD-L were fused to the C-terminus of GFP, and co-
transfected into cultured cells with Flag-tagged WT long form. PNKD-L multimerizes through an interaction of the N-terminal region 
and this interaction requires amino acids 132–166 (Fig. A). PNKD mutations do not interfere with this interaction (Fig. B). To test 
whether MUT PNKD-L might have an effect on the WT isoform, we tagged WT PNKD-L with GFP and co-expressed with FLAG-
tagged PNKD-L WT or MUT in cultured cells and examined protein levels of the WT form (and vice versa) (Fig. C). Co-expression 
with WT or MUT PNKD-L did not significantly affect WT PNKD-L protein levels in cultured cells, suggesting that although PNKD-L 
can self-associate, the MUT PNKD protein does not destabilize WT PNKD in vitro. Similar studies with short and medium isoforms 
showed the same result. Although short and long isoforms can heteromultimerize, they do not affect WT protein levels 
(Supplementary Material, Fig. S4).  
4 4
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Subcellular localization of PNKD-L 
A recent study suggested that PNKD-L localized to mitochondria in Cos7 cells (6) instead of cellular membrane (4) in HEK293 
cells. To clarify this controversy, we repeated experiments with mitochondrial staining in Cos7 cells since our original experiments 
were in HEK293 cells. When overexpressed, both PNKD-L–FLAG and PNKD-L–GFP fusion proteins show strong cellular 
membrane-localization patterns in Cos7 cells, and no co-localization with mitochondria was found (Supplementary Material, Fig. 
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S5). These findings were further supported by confocal microscopy of COS7 cells expressing PNKD–GFP (Supplementary 
Material, Fig. S6). Cellular fractionation of extracts of HEK293 cells overexpressing PNKD was also performed. Western blots 
showed no PNKD in fractions that were positive for a mitochondrial marker and abundant PNKD signal in the soluble fractions 
(Supplementary Material, Fig. S7). All PNKD isoforms and constructs were sequence confirmed. 
We then performed experiments in a cell line that is more relevant to the expression pattern of PNKD. SH-SY5Y is a cell line 
derived from a human neuroblastoma. We transfected PNKD-L or PNKD-L–GFP fusion constructs into cultured SH-SY5Y cells and 
used two different approaches to examine the subcellular localization of PNKD-L: PNKD-L–GFP fluorescence, and immunostaining 
with an antibody against untagged PNKD-L. Representative cells expressing PNKD-L–GFP (Fig. A) and untagged PNKD-L 
stained with antibody (Fig. B) are shown, and the results suggest that PNKD-L is a membrane-associated protein.  
In addition to membrane localization, we also observed some irregularly shaped cytoplasmic speckles in ~50% of the transfected 
cells, often close to the membrane. We then stained the cells with antibodies for the late endosomal marker M6PR and showed co-
localization with PNKD-L, suggesting that cytoplasmic PNKD-L remains in late endosomes before trafficking to the cell membrane 
(Fig. C). No notable differences in localization of PNKD-L WT and MUT forms were seen in SH-SY5Y or HEK293 cells. 
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PNKD enzymatic activity assay 
PNKD-L has a motif homologous to a conserved enzymatic domain. The C-terminal β-lactamase domain sequence similarity 
between human PNKD-L and HAGH is 58%, and leaves the unique 117 amino acid N-terminus of PNKD-L unaligned. HAGH 
hydrolyzes SLG to D-lactic acid and reduced glutathione. To test whether PNKD-L might hydrolyze SLG, we expressed and 
purified PNKD-L and HAGH from HEK293 cells using antibody cross-linked gel and measured SLG hydrolytic activity 
(Supplementary Material, Fig. S8). When incubated with SLG at 37°C, HAGH hydrolyzed SLG robustly. PNKD-L has extremely low 
but consistent SLG hydrolysis activity, showing an increasing hydrolysis within the range of soluble concentrations of SLG (0–1800 
μM). This indicates that hydrolysis of SLG in vivo by PNKD-L is unlikely to be physiologically relevant. To further examine whether 
PNKD-L can efficiently hydrolyze SLG in vivo, we tested the ability of human PNKD-L to rescue HAGH activity in a Drosophila 
melanogaster strain lacking endogenous HAGH activity due to the presence of a homozygous null mutation in the Drosophila hagh 
gene (CG4365, Fig. A).  Introduction of a Drosophila HAGH transgene into the null background restores HAGH activity to a higher 
level than that observed in the WT fly, while introduction of a human PNKD-L transgene into the same null background shows no 
rescue of SLG metabolism, further supporting the idea that PNKD-L does not use SLG as an in vivo substrate.  
Sequence alignment and enzyme kinetics suggest that PNKD-L substrate may be an (as yet, unknown) α-hydroxythioester, and 
similar to HAGH, PNKD-L may be involved in a chain reaction to detoxify an α-ketonaldehyde product in CNS neurons using 
reduced glutathione (GSH) as a co-factor. The mutant Pnkd transgene or knockout of Pnkd may cause accumulation of some α-
hydroxythioester and reciprocally decrease neuronal GSH. To test this hypothesis, we measured GSH levels in the frontal cortex in 
a cohort of 15-week-old Pnkd null mice (KO, n = 8), mut-Tg mice (mut-Tg, n = 12) and WT (n = 13) littermates. Figure B shows 
that KO and mut-Tg mice have significantly lower glutathione levels (~20% lower) in the frontal cortex compared with WT 
littermates, suggesting that glutathione-related metabolic changes are present in these mice even when there is no attempt to 
precipitate attacks. 
6
6
DISCUSSION 
PNKD is a movement disorder with symptoms precipitated by stress and alcohol or caffeine consumption. PNKD patients appear 
completely normal between attacks (1,4,5), although there is anecdotal evidence of increased migraine prevalence in PNKD 
patients (L.J.P., unpublished data). The C-terminus of Pnkd-L is homologous to human HAGH, which is important for the second 
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catalyzed step in MG detoxification. MG is a toxic byproduct of glycolysis and exists in many natural products including alcohol and 
coffee (12). We show that PNKD-L recognizes the same substrate in this pathway (SLG), but catalyzes the same reaction as 
HAGH at a very low level, suggesting that a similar α-hydroxythioester substrate is likely to be the physiologically relevant 
substrate for PNKD-L activity in the CNS (13,14). PNKD-L may function in a pathway(s) to detoxify an α-ketonaldehyde product in 
cells using GSH as a co-factor in CNS neurons, as suggested by decreased GSH levels in Pnkd KO mice. The in vivo substrate(s) 
for PNKD-L is unknown but GSH levels in cortical lysates from Pnkd KO mice were decreased, suggesting the reaction catalyzed 
by Pnkd-L may be important for regeneration of GSH in CNS neurons. GSH is essential for maintaining proper cellular redox status 
and protecting against toxicity and other stress conditions that may occur in neurons (11,15). Neurons are vulnerable to stress 
conditions such as hypoxia, ischemia, altered pH and oxidative stress. Such conditions are often accompanied by an increased 
presence of cellular reactive oxygen species and decreased levels of cellular GSH (16). Reactive oxygen species are free radicals 
or reactive molecules containing oxygen atoms, such as superoxide or hydrogen peroxide, and are cleared from cells by the action 
of superoxide dismutase or glutathione peroxidase. GSH is an important factor involved in clearing reactive oxygen species, and 
the level of GSH is an indicator of cellular redox status (17,18). It has been reported that increased levels of GSH can protect 
against neuronal death caused by kainic acid or glutamate toxicity (10,19,20). Conversely, reduced GSH levels contribute to 
neuronal death in Down's syndrome and ALS-like transgenic mouse models (17,21). In our Pnkd-deficient mice, GSH levels were 
~20% lower in the cortex, suggesting impaired redox regulation.
In the present study, we characterized an N-terminal cleavage event and measured protein stability of PNKD-L. The mutant PNKD-
L isoform is resistant to N-terminal cleavage and is less stable than the WT protein. Levels of the mutant PNKD-L protein in mut-Tg 
X Pnkd–/– mouse brains (with one to two copies of mutant Pnkd transgene) are lower than endogenous WT Pnkd-L in WT 
heterozygous littermate brains.
PNKD-L is specifically expressed in the CNS; the membrane and endosome localization pattern suggests that PNKD-L may be 
involved in vesicle recycling or membrane protein transport in CNS neurons. When neurons are under stress or undergoing 
dramatic changes in redox status, mutant PNKD-L may fail to maintain necessary levels and lead to malfunction of motor circuits. 
Another possibility is that post-translational modification may affect PNKD-L itself or the associated protein complex in vivo function 
in CNS neurons. It has been reported that disease mutations in the TorsinA protein affect the protein stability, nuclear envelope, 
cellular trafficking of the dopamine transporter to the cellular membrane and also have an effect on synaptic vesicle recycling in SH-
SY5Y cells (22–28). There is a growing body of evidence suggesting that dopaminergic neurons are affected in mouse models of 
generalized dystonia and PNKD (26,29, Lee et al., submitted for publication). Identifying PNKD-L-associated proteins involved in 
membrane protein trafficking in CNS dopaminergic neurons will likely address this issue and increase our knowledge of the 
molecular mechanism of dystonia.
We have previously shown that the long isoform of PNKD is localized to the cellular membrane in HEK293 cells, the medium 
isoform to mitochondria and the short isoform is widely distributed in cells (4). A recent study showed a contradictory localization 
pattern in Cos7 cells where PNKD-L and PNKD-S isoforms localized to mitochondria and PNKD-M localized to the Golgi 
apparatus, ER and plasma membrane (6). We reasoned that these disparate results may have been explained by the use of 
different cell lines. However, when we repeated these experiments in Cos7 cells, we still observed a membrane-localization pattern 
with some cytosolic pellets for both human PNKD-L–GFP and PNKD-L–FLAG constructs that did not co-localize with mitochondrial 
markers (Supplementary Material, Figs S5–S7) (4). Since PNKD-L is specifically expressed in CNS neurons, we chose a 
neuroblastoma-derived cell line SH-SY5Y (as a ‘neuron-like’ cell line) and have shown that PNKD-L is specifically localized to the 
cell membrane and late endosomes. SH-SY5Y is a cell line derived from a human neuroblastoma cell line, and HEK293 cells were 
derived from human kidney epithelia. PNKD-L antibody staining revealed that the long isoform of human PNKD localizes in a cell 
membrane pattern in both cell lines. Similar findings were seen when cells were transfected with a clone encoding a PNKD-L–GFP 
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fusion protein. A localization pattern of endogenous Pnkd-L in cultured primary neurons or brain slices would address this issue. 
However, due to the low protein levels of endogenous Pnkd-L, immunostaining in mouse brain slices and cultured primary neurons 
failed to generate high-resolution images of cellular localization. We considered the possibility that a sequence variant or mutation 
in the constructs used in these studies might be causing our disparate results, but we resequenced all constructs used and they 
were confirmed to be correct. Another possibility worth investigating involves the antibodies used by Ghezzi et al. All of the 
antibodies used for the immunofluorescence co-localization studies were generated in mice (Figs  and  and Supplementary 
Material, Fig. S1 in ref. 6), it is possible that there was cross-staining by secondary antibodies. There was insufficient detail in the 
description of methods regarding the antibodies used and of primary antibody incubation sequence to assess this possibility. We 
chose antibodies from different species (mouse and rabbit) to avoid cross-staining, and we also used GFP fusion proteins and 
MitoTracker dye for co-localization studies (Fig.  and Supplementary Material, Figs S5 and S6). We consistently observed a 
cellular membrane-localization pattern for PNKD long form. Another possible explanation is that PNKD was expressed at much 
higher levels in the studies of Ghezzi et al. and that this led to aberrant expression of the protein. Again, insufficient details are 
given to allow assessment of this possibility.
3 5
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In addition to microscopy, we also looked into the mitochondrial protein database for all PNKD isoforms. MitoCarta is an inventory 
of >1000 mouse genes encoding proteins with strong support for mitochondrial localization (30). This database was generated by 
performing mass spectrometry of mitochondria isolated from 14 tissues, assessing protein localization of GFP-tagged fusion 
proteins, and using a Bayesian approach to integrate these results with six other genome-scale data sets of mitochondrial 
localization. In querying the mass spectrometry data set for peptides from the PNKD protein, there was strong support for the short 
isoform to be localized to mitochondria with two peptides unique to this isoform being seen multiple times in multiple tissues 
(Supplementary Material, Fig. S9). In contrast, no peptides were seen from the β-lactamase domain of PNKD-L and PNKD-M. One 
peptide shared between the long and short isoforms was seen only rarely and not in any of the four CNS tissues. Absence of 
peptides in the database does not absolutely prove that a protein is not localized in mitochondria. However, in light of other data 
presented here, it further supports our claim that PNKD-L is not mitochondrial.
Study of novel genes identified using forward genetics is challenging but exciting, mutations in such disease genes can yield 
insights into new pathways and biological functions. In this report, we described an alteration of protein stability caused by point 
mutations in PNKD; this cellular membrane protein is likely involved in a reaction catalyzing metabolism of an α-hydroxythioester, 
and ablation or mutation of PNKD leads to a decrease in GSH levels in the brain. Findings from biochemical studies and mouse 
models will provide insight into the normal function of PNKD and dysfunction when mutated. Understanding of PNKD 
pathophysiology may facilitate understanding of the etiology of other movement disorders and lead to novel targets for 
development of therapies for this and other episodic disorders.
MATERIALS AND METHODS 
SLG hydrolysis and luciferase assays 
The SLG hydrolysis assay was performed in a 96-well plate. The concentration of SLG (0–2000 nM) was monitored by absorption 
at 240 nm using the Spectra Max 190 (Molecular Devices). Kinetic measurement of SLG hydrolysis was detected by the changes 
in SLG concentration as a function of the reaction time in the presence of 200 μM 5,5′-dithiobis(2-niotrobenzoate). Reactions were 
carried out at 37°C in 200 μl Tris–HCl, pH 7.5 with a range of SLG (0–2000 nM) and ~10 ng of purified protein. HAGH and human 
PNKD-L protein concentrations were measured with the BCA Protein Assay Kit (Pierce) and equal amounts of protein were 
assayed in each well. Data are from three independent experiments and are analyzed by SigmaPlot 11.0. Renilla luciferase was 
used as an internal control of transfection efficiency in cell culture experiments. Luciferase activity was measured using a Dual 
Luciferase Assay Kit (Promega) on the Genios Pro (Tecan). 
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Generation of transgenic and knockout flies 
Drosophila HAGH null animals (dhaghEX10) were generated by excising a transposable element in dhagh (P[SUPor-P] 
CG4365KG07968, Bloomington Stock #14677). This removed 837bp from the HAGH coding region which was verified by northern 
blot analysis and sequencing (data not shown).  Enzymatic tests of protein extracts from this viable fly strain revealed no remaining 
HAGH activity. Human UAS-Pnkd-L transgenics were made by placing the coding region of Pnkd-L into pUAST which was injected 
into embryos with a transposase plasmid to generate a stable genomic insertion of the transgene.  dhagh was cloned by reverse 
transcription polymerase chain reaction (RT-PCR) and placed into pUAST to generate the UAS-DHAGH transgenic animal. These 
transgenes were expressed by driving with daughterless-GAL4 in a homozygous dhaghEX10 background to test the ability of each 
transgene to rescue HAGH activity. All clones were sequence confirmed. 
Drosophila HAGH enzymatic assay 
Each sample was prepared by collecting five flies of the appropriate genotype. Flies were mechanically ground and sonicated in a 
10 mM sodium phosphate buffer solution (pH 7.4).  Samples were spun down in a table top centrifuge (10 min at 14 000 rpm in 4°
C) and the supernatant was removed and spun a second time in an ultracentrifuge (30 min at 50 000g, 4°C).  Protein 
concentrations from the second centrifugation were measured and 8 μg of protein/sample was loaded into a 96-well plate with 50 
mM Tris–HCl buffer (pH 7.4) and 3 mM S-lactoylglutathione. SLG concentrations were measured at 240 nm at 1min increments for 
30 min using the Spectra Max 190 (Molecular Devices). 
mut-Tg mice and Pnkd knockout mice 
Mutant Pnkd transgene mice were made using a mouse BAC carrying A7V and A9V mutations in the mouse Pnkd ortholog; Pnkd 
null mice were made by deleting exons 5–9 of the mouse Pnkd ortholog. Generation and characterization of these two lines are 
described in a separate manuscript (Lee et al., submitted for publication). 
GSH assay in mut-Tg and Pnkd knockout mice 
Three-month-old mut-Tg, PnkdD null mice and WT littermates were sacrificed and cerebral cortices were harvested, weighed, 
snap frozen in liquid nitrogen and stored at −80°C for later protein extraction and total glutathione assays. Total glutathione in 
mouse brain extracts was analyzed using a Total Glutathione Quantification Kit (Dojindo) on a Spectra Max 190 (Molecular 
Devices). Results were normalized according to brain sample weight. 
Plasmids and antibodies 
Full-length cDNAs of three human PNKD isoforms were previously described (4). PNKD disease mutations (A7V/A9V, A33P) were 
introduced into human PNKD constructs (L and S isoforms) with the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene). 
Two additional mutations in the region of the PNKD mutations (A15G/R16G), and a mutation further away from the N-terminus 
(C85G) were also engineered into the PNKD-L and PNKD-S constructs. Subclones of PNKD-L were obtained by RT–PCR from 
human brain cDNA using Expanded High Fidelity PCR (Roche). HAGH was obtained by RT–PCR from human brain cDNA. Full-
length or domains of genes of interest were constructed on pCMV-Tag2 (Stratagene), pEF6/Myc-His (Invitrogen), pEGFP-N1 and 
pEGFP-C3 (Clontech) vectors using appropriate restriction enzyme sites to generate fusion proteins. All constructs were sequence 
confirmed. Constructs in Figure B encoded the following PNKD-L amino acid residues: (i) 75–385, (ii) 93–385, (iii) 132–385 and 
(iv) 167–385. 
A Rabbit antibody (C2235) was raised against the C-terminus peptide of PNKD (DDYSRAQLLEELRRLKDMHKSK, 363–385) (Lee 
et al., submitted for publication). Anti-GFP (ab290) and anti-M6PR (ab12894) are from Abcam, anti-Flag (F7425) is from Sigma, 
anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (MAB374) is from Chemicon, chicken anti-HAGH (A21981) is from 
6
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GenWay and anti-Flag M2-conjugated agarose is from Sigma. 
Cell culture, transfection and immunofluorescence 
SH-SY5Y cells were maintained in the 1:1 mixture of Eagle's minimum essential medium and Ham's F12 Medium supplemented 
with heat-inactivated fetal bovine serum, 10% (v/v). HEK293 (ATCC) cells were maintained in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% (v/v) heat-inactivated fetal bovine serum. For protein expression and luciferase assays, HEK293 
cells were seeded in 60 mm dishes or 12-well plates overnight, and transfected with plasmid using Lipofectamine 2000 (Invitrogen) 
when they reached 80–90% confluence. Cells were harvested 24 h post-transfection. SH-SY5Y cells were cultured on two-well 
slides. Cells were fixed with 4% paraformaldehyde solution and subjected to a standard immunostaining protocol. 
Co-immunoprecipitation and western blot 
HEK293 cells were transfected with Tag2B-PNKD-L and N1-PNKD-L constructs. Cells were harvested 24 h post-transfection, 
lysed with M-PER (PIERCE) reagent supplemented with benzonase nuclease (Novagen) and complete protease inhibitors 
(Roche). Soluble lysate was incubated with M2 agarose (Sigma) overnight at 4°C. M2 agarose was washed five times with 0.25% 
Triton X-100 PBS followed by three times with 0.5% Triton X-100 PBS, then bound protein was eluted using 1X Sample Loading 
Buffer (Invitrogen) and heated to 100°C for 5 min. Lysate and eluate were resolved on 10% glyceraldehyde 3-phosphate 
dehydrogenase (SDS-PAGE) gels, transferred to NC membranes (Millipore) and probed with antibody according to a standard 
western blotting protocol. 
Pulse chase assay 
HEK293 cells were transfected with plasmids expressing Tag2B-PNKD-L WT or Tag2B-PNKD-L MUT. After 24 h, transfected cells 
were washed twice with fresh culture medium and starved for 1 h in DMEM without L-methionine and L-cysteine (Gibco). Fresh 
culture medium containing 35S labeled cysteine/methionine (EXPRE35S, PerkinElmer Life Sciences) at 200 µCi/ml was then 
added. After 20 min of incubation, the radioactive medium was removed and the cells were washed three times with fresh DMEM 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum and incubated at 37°C. At each time point (0, 10, 20, 40 and 60 
min), cells were washed twice with PBS, harvested and lysed in M-PER lysis buffer (PIERCE) supplemented with complete 
protease inhibitors (Roche). Flag-PNKD-L was immunoprecipitated with anti-flag M2 agarose (Sigma), resolved on SDS–PAGE 
gels and subjected to radiography. 
Quantitative real-time PCR analysis 
Total RNA was isolated from freshly harvested mouse cortex using RNeasy Midi Kit (Qiagen), and 2 μg total RNA from each 
sample was used for reverse transcription using cDNA reverse transcription kit according to the manufacturer's instructions 
(Invitrogen). Genomic DNA was removed by DNase digestion. Quantitative real-time PCR was performed using a 7900HT FAST 
Real-time PCR System with SYBR Green reagents (Applied Biosystems). Dilution series and standard curves of Pnkd and GAPDH 
were amplified on each plate for each experiment. Transcript levels for PNKD were normalized to GAPDH mRNA levels according 
to the standard procedures. 
SUPPLEMENTARY MATERIAL 
Supplementary material is available at HMG online.
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Figures and Tables 
 
Figure 1. 
PNKD protein carrying disease mutations is degraded faster than WT PNKD. (A) HEK293 cells expressing MUT PNKD show lower 
protein levels than those expressing WT PNKD. PNKD-L WT and MUT (upper panel); and PNKD-S WT and MUT (lower panel) are 
shown. Equal volumes of soluble cell lysate were loaded in each lane. (B) The CHX assay in cells expressing WT or MUT PNKD 
long form. Cells were treated with CHX for 1, 2, 3, 4 or 6 h. Cells were transfected with 1 μg WT and 2 μg MUT to achieve similar 
protein levels at the 0 time point, data in the graph are from three independent experiments. Error bars indicate standard errors, *P 
< 0.05 (Student t-test). (C) 35S methionine-labeled Pulse Chase assay in cells expressing WT or MUT PNKD-L. Cells were 
collected at 0, 10, 20 or 30 min post-isotope labeling. (D) Pnkd-L protein levels in brain extracts from mice that carried different 
copy numbers of WT Pnkd and mutant Pnkd BAC transgene. The mutant BAC transgene in mut-Tg mice mimics endogenous 
Pnkd expression but has lower protein levels. 
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Figure 2. 
PNKD-L is degraded through the proteasomal, lysosomal and autophagy pathways. (A) The PNKD protein (upper panel PNKD-L 
and lower panel PNKD-S) is found in both membrane and cytosolic fractions. (B and C) Cells expressing equal amounts of WT or 
MUT PNKD-L were treated with DMSO, lactacystine (proteasome inhibitor), MG-132 (proteasome and lysosome inhibitor), 
chloroquine (lysosome inhibitor) and 3-MA (autophagy inhibitor), respectively, and lysates were extracted into membrane (B) and 
cytosolic (C) fractions. The membrane-associated WT PNKD-L protein is degraded through the proteasomal and lysosomal 
pathways (lanes 2–4), PNKD-L MUT is also degraded through the autophagy pathway (lane 5). The star marks the band with 
increased intensity of PNKD-L MUT proteins versus DMSO control when treated with 3-MA. (C) The cytosolic PNKD-L protein is 
degraded through the proteasomal pathway (lanes 2 and 3). Integrin αV and GAPDH were used as transmembrane protein and 
cytosolic protein controls, respectively. 
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Figure 3. 
WT PNKD-L is cleaved at its N-terminus, while mutant PNKD-L is resistant to cleavage. (A) A FLAG epitope was added to the N-
terminus of PNKD-L WT or MUT, PNKD-M, PNKD β-lactamase domain, and HAGH. Cell lysates were blotted with FLAG or PNKD-
L antibody. (B) GFP was fused to the N-terminus of PNKD-L WT or MUT, PNKD-S WT or MUT, and a fragment containing amino 
acids 1–79 of the PNKD N-terminus (N-79). Cell lysates were blotted with GFP antibody. Cleaved GFP was detected in all 
constructs that contain WT N-terminal sequences, the arrowheads indicate the cleaved N-terminal GFP fragments which are 
slightly larger than GFP alone. (C) GFP was fused to the N-terminus of PNKD-L WT, MUT, A33P, A15G/R16G or PNKD-S WT, 
C85G, A15G and R16G. GFP cleavage was only detected in WT and C85G. (D) The CHX assay in cells expressing PNKD-L A33P 
and WT, PNKD-S A15G and WT shows that these mutations also lead to faster degradation. 
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Figure 4. 
PNKD can self-associate, but PNKD-MUT does not have a dominant negative effect on WT protein levels. (A) PNKD-L WT 
subclones of different lengths were ligated into GFP vectors (C-terminal) and tested for possible association with FLAG-tagged (C-
terminal) PNKD-L WT by Co-IP. The shaded rectangle indicates the 1–79 amino acids. N-terminal sequence shared by long and 
short isoforms, dark rectangle indicates the β-lactamase domain. The C-terminal 219 amino acid fragment of PNKD-L does not 
associate with PNKD-L. (B and C) FLAG-tagged (C-terminal) PNKD-L WT and MUT were co-transfected into HEK293 cells with 
GFP-tagged (C-terminal) PNKD-L WT and MUT. Cells were transfected with the same amount of DNA. (B) The protein was 
precipitated by an anti-FLAG M2 agarose (Sigma) and the elution was blotted for associated protein using a GFP antibody. (C) 
Protein levels of WT or MUT forms were detected by an anti-FLAG or anti-GFP antibody. No change in protein levels was found 
when co-expressing WT and MUT isoforms. 
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Figure 5. 
Cellular localization of the long PNKD isoform. PNKD constructs were transfected into SH-SY5Y cells to express PNKD-L or PNKD-
L–GFP fusion protein (C-terminal tag). (A) PNKD-L–GFP WT and mutant (MUT) forms are localized to the cellular membrane; (B) 
immunostaining of PNKD-L WT and MUT forms with PNKD-L antibody; (C) PNKD-L–GFP is localized to both the cellular 
membrane and late endosomes, indicated by mannose 6 phosphate receptor (M6PR) immunostaining. Cellular localization 
patterns of PNKD-L in (A) and (C) are in an approximate 1:1 ratio in transfected SH-SY5Y cells. 
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Figure 6. 
PNKD-L does not rescue lost HAGH activity. (A) Protein extracts from a Drosophila HAGH homozygous null mutant (circles) lose 
the ability to hydrolyze SLG when compared with protein extracts from WT flies (triangles). When Drosophila HAGH is replaced in 
the null mutant background by transgenic over-expression (squares), SLG hydrolytic activity is restored to levels even greater than 
detected in WT flies (triangles). However, when human PNKD-L is expressed on a Drosophila HAGH mutant background, no 
rescue of SLG hydrolysis is detected (x's). (B) Mut-Tg mice and KO mice have lower glutathione levels in extracts from the cortex 
compared with WT littermates under normal conditions. Error bars indicate standard errors (WT, n = 13; mut-Tg, n = 12; KO, n= 8). 
*P < 0.05 and **P < 0.01 from WT mice (Student's t-test). 
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